The quick comparison
Thymulin and thymosin alpha-1 are peptides: short chains of amino acids. Both have a thymus connection. That resemblance doesn’t show that they do the same thing.
Thymulin needs zinc for activity. Thymosin alpha-1 is a different molecule, and its man-made counterpart is called thymalfasin. Here are the differences worth keeping handy.
| A useful distinction | Thymulin | Thymosin alpha-1 |
|---|---|---|
| Amino acids in the chain | Nine | 28 |
| Detail to remember | Active form includes zinc | Thymalfasin has the same sequence |
| Research discussed here | Zinc studies and mouse gene research | Trials in people |
| FDA-approved medicine | No | No |
Look at what went into the study
The human thymulin study changed zinc availability. It found that thymulin activity could recover when zinc was restored. That tells us about zinc and thymulin working together; it doesn’t test thymulin as a medicine.
The mouse asthma experiment did something else again. It delivered instructions so cells could make thymulin, and lung problems improved. An animal gene treatment can’t establish a benefit from peptide injections in people.
For thymosin alpha-1, the larger sepsis trial gave adults the peptide or a dummy treatment. There was no clear difference in deaths over 28 days. SciClone Pharmaceuticals funded the trial, and some authors received company grants or fees. SciClone makes Zadaxin, the thymalfasin medicine.
A longer research history doesn’t pick a winner
Thymosin alpha-1 has more human trial evidence. That includes a major result that didn’t confirm the hoped-for benefit. Thymulin leaves much more unanswered about treatment with thymulin itself in people, including long-term safety.
Neither story settles which treatment fits a person. Neither has FDA approval as a medicine.
Compounded products are not FDA-approved, even when prescribed. The thymulin page explains its gaps. It’s fine to finish with better questions instead of a favourite.